Abstract
BackgroundDuring Phase 1 of the 52 wk open-label PRIZE study treatment of patients (pts) with early (mean 6 mos.) moderate-severe rheumatoid arthritis (RA), who were methotrexate (MTX)/biologic naïve, with 50...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have